ELOX

Eloxx Pharmaceuticals, Inc.

There isn't enough reported data to score ELOX yet.

ELOX Fundamentals

MetricStatus
Unavailable
Under pressure
Unavailable
Unavailable

ELOX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.

ELOX PE Valuation

ELOX has no meaningful PE right now: it lost money over the past year.

ELOX Forward outlook

There aren't enough analyst estimates for ELOX to show an outlook.

ELOX Risk to reward

ScenarioChangePrice
UpsideUnknown—
DownsideUnknown—

Calculated from the latest close: $12.89 on Nov 12.

There is not enough scenario data to assess ELOX's risk to reward.

ELOX Earnings Per Share

Q4 2021: $-418.00Q1 2022: $-378.40Q2 2022: $-193.60Q3 2022: $-184.80
Q4 2021: $-418.00Q1 2022: $-378.40Q2 2022: $-193.60Q3 2022: $-184.80
QuarterTTM EPSYoY
Q3 2022-$184.80+$264.00
Q2 2022-$193.60+$277.20
Q1 2022-$378.40-$57.20
Q4 2021-$418.00-$39.60
Q3 2021-$448.80-$8.80
Q2 2021-$470.80+$39.60
Q1 2021-$321.20+$277.20
Q4 2020-$378.40+$211.20

ELOX is still losing money, but far less than before: $184.80 per share over the past year, against $646.80 at its worst in early 2019.

ELOX Quarterly Revenue

Q4 2021: --Q1 2022: --Q2 2022: --Q3 2022: --Q4 2022: --Q1 2023: --Q2 2023: --Q3 2023: --Q1 2025: $0Q2 2025: $0Q1 2026: --Q2 2026: --
Q4 2021: --Q1 2022: --Q2 2022: --Q3 2022: --Q4 2022: --Q1 2023: --Q2 2023: --Q3 2023: --Q1 2025: $0Q2 2025: $0Q1 2026: --Q2 2026: --

ELOX Free Cash Flow

Q4 2021: −$10MQ1 2022: −$10MQ2 2022: −$10MQ3 2022: −$7MQ4 2022: −$6MQ1 2023: −$7MQ2 2023: −$2MQ3 2023: −$3MQ1 2025: $1MQ2 2025: −$2MQ1 2026: −$5MQ2 2026: −$5M
Q4 2021: −$10MQ1 2022: −$10MQ2 2022: −$10MQ3 2022: −$7MQ4 2022: −$6MQ1 2023: −$7MQ2 2023: −$2MQ3 2023: −$3MQ1 2025: $1MQ2 2025: −$2MQ1 2026: −$5MQ2 2026: −$5M
QuarterFree cash flowYoY
Q2 2026-$4.8M-$3M
Q1 2026-$5.5M-553%
Q3 2023-$3.5M+$3.5M
Q2 2023-$2.1M+$7.7M
Q1 2023-$6.8M+$2.7M
Q4 2022-$5.7M+$4.3M
Q2 2022-$9.8M+$43K
Q1 2022-$9.5M-$1.8M

ELOX has burned cash in almost every quarter: −$11M over the past year, against −$18M the year before.

ELOX Total Shares

Q4 2021: 159,006Q1 2022: 196,934Q2 2022: 196,941Q3 2022: 196,946Q4 2022: 196,937Q1 2023: 196,941Q2 2023: 201,124Q3 2023: 249,790Q1 2025: 345,924Q2 2025: 347,000
Q4 2021: 159,006Q1 2022: 196,934Q2 2022: 196,941Q3 2022: 196,946Q4 2022: 196,937Q1 2023: 196,941Q2 2023: 201,124Q3 2023: 249,790Q1 2025: 345,924Q2 2025: 347,000
PeriodChange %Net change
Quarterly+0.3%+1.1K shares
1 year+76%+150K shares
3 years+280%+256K shares
5 years+325%+265K shares
Available history+455%+284K shares

ELOX has 347,000 diluted shares, up 76% from a year ago.

ELOX Net Leverage

ELOX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.

ELOX Weekly Momentum

MetricValueStatus
RSI49.3Neutral
Stochastic11.7Oversold

ELOX's weekly RSI is 49 (neutral) and its Stochastic is 12 (oversold).

ELOX PE vs Healthcare Sector

ELOX has no meaningful PE right now: it lost money over the past year.

ELOX Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$13.65.3% below
20 week MA$14.813% below

ELOX is in a downtrend: it's below all two of its weekly moving averages, and 13% below its 20-week average.

ELOX Yearly ROI

YearStart priceEnd priceROI
2026 YTD$13.5$12.9-4.7%

It's down 4.7% so far in 2026.

Give your agent the market.

Get API key